ALECTOR INC. - COMMON STOCK

Alector Announces Proposed Public Offering of Common Stock

16 Jan 2024 15:01:00 By Nasdaq GlobeNewswire

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

28 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Alector to Participate in the Stifel Healthcare Conference

08 Nov 2023 06:00:01 By Nasdaq GlobeNewswire

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

07 Nov 2023 15:05:01 By Nasdaq GlobeNewswire

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

27 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease

07 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

Alector to Participate in Upcoming Healthcare Conferences

31 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Alector Reports Second Quarter 2023 Financial Results and Provides Business Update

03 Aug 2023 15:05:01 By Nasdaq GlobeNewswire

Alector to Host Mid-Year Earnings Conference Call

27 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

06 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Alector Reports First Quarter 2023 Financial Results and Provides Business Update

04 May 2023 15:05:00 By Nasdaq GlobeNewswire

Alector to Participate in the BofA Securities 2023 Healthcare Conference

02 May 2023 06:00:00 By Nasdaq GlobeNewswire

Alector to Participate in Upcoming Healthcare Conferences

01 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

28 Feb 2023 15:05:01 By Nasdaq GlobeNewswire

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

08 Dec 2022 15:30:00 By Nasdaq GlobeNewswire

Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

29 Nov 2022 10:05:00 By Nasdaq GlobeNewswire

Alector Reports Third Quarter 2022 Financial Results and Provides Business Update

08 Nov 2022 15:05:01 By Nasdaq GlobeNewswire

Alector to Participate in Upcoming Healthcare Conferences

07 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 Nov 2022 15:30:00 By Nasdaq GlobeNewswire

Alector Announces Promotion of Clare Hunt to Chief People Officer

13 Oct 2022 07:00:01 By Nasdaq GlobeNewswire